Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Figen Akmut"'
Autor:
Marcus Matthias Schittenhelm, Bianca Walter, Vasileia Tsintari, Birgit Federmann, Mihada Bajrami Saipi, Figen Akmut, Barbara Illing, Ulrike Mau-Holzmann, Falko Fend, Charles Darin Lopez, Kerstin Maria Kampa-Schittenhelm
Publikováno v:
EBioMedicine, Vol 42, Iss , Pp 340-351 (2019)
Background: Apoptosis-stimulating Protein of TP53-2 (ASPP2) is a tumor suppressor enhancing TP53-mediated apoptosis via binding to the TP53 core domain. TP53 mutations found in cancers disrupt ASPP2 binding, arguing for an important role of ASPP2 in
Externí odkaz:
https://doaj.org/article/162a0dcf7af743ecb55394431c13be11
Autor:
Bianca Walter, Marcus M Schittenhelm, Kerstin M Kampa-Schittenhelm, Falko Fend, Mihada Bajrami Saipi, Birgit Federmann, Vasileia Tsintari, Charles D. Lopez, Ulrike A. Mau-Holzmann, Figen Akmut, Barbara Illing
Publikováno v:
EBioMedicine. 42:340-351
Background Apoptosis-stimulating Protein of TP53-2 (ASPP2) is a tumor suppressor enhancing TP53-mediated apoptosis via binding to the TP53 core domain. TP53 mutations found in cancers disrupt ASPP2 binding, arguing for an important role of ASPP2 in T
Autor:
E. Schleicher, I. Bonzheim, S.T. Dreher, T. Ganief, Marcus M. Schittenhelm, L. Haeusser, M. Bonin, T. Haverkamp, W. Vogel, Barbara Illing, H.J. Bühring, Gunnar Blumenstock, Figen Akmut, Kerstin M Kampa-Schittenhelm, Vasileia Tsintari, Ulrike A. Mau-Holzmann
Publikováno v:
EBioMedicine
EBioMedicine, Vol 54, Iss, Pp-(2020)
EBioMedicine, Vol 54, Iss, Pp-(2020)
Background: Overriding the differentiation blockage in acute myeloid leukemia (AML) is the most successful mode-of-action in leukemia therapy – now curing the vast majority of patients with acute promyelocytic leukemia (APL) using all-trans retinoi
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
Autor:
Figen Akmut, Katharina Henriette Rasp, Kerstin M Kampa-Schittenhelm, Barbara Illing, Hartmut Döhner, Michael Heinrich, Marcus M Schittenhelm, Konstanze Döhner
Publikováno v:
Molecular Cancer
Background Dysregulation of the PI3Kinase/AKT pathway is involved in the pathogenesis of many human malignancies. In acute leukemia, the AKT pathway is frequently activated, however mutations in the PI3K/AKT pathway are uncommon. In some cases, const
Autor:
Barbara Illing, Figen Akmut, Lothar Kanz, Kerstin M Kampa-Schittenhelm, Marcus M Schittenhelm, Julia Frey, Abhijit Ramachandran, Katja Schuster
Publikováno v:
Blood. 124:2230-2230
Activating mutations of the class III receptor tyrosine kinases FLT3 and KIT are associated with certain human neoplasms, including hematologic malignancies, i.e. the majority of patients with systemic mast cell disorders (KIT) and subsets of patient
Autor:
Figen Akmut, Marcus M Schittenhelm, Barbara Illing, Charles D. Lopez, Kerstin M Kampa-Schittenhelm
Publikováno v:
Blood. 124:2221-2221
Inactivation of the p53 pathway is an universal event in human cancers. As p53 mutations are rare in de novo acute leukemias, the p53-pathway must be inactivated by other mechanisms instead. The Apoptosis stimulating Protein of p53-2 (ASPP2) is a hap
Autor:
Kerstin M Kampa-Schittenhelm, Tanja Grandl, Figen Akmut, Barbara Illing, Marcus M Schittenhelm
Publikováno v:
Blood. 122:3952-3952
Introduction Activating mutations of the KIT class III receptor tyrosine kinase (TK) are associated with the pathophysiology of acute leukemia, especially core binding factor leukemia (CBFL), and systemic mastocytosis (SM). Despite considerable antip
Autor:
Kerstin M Kampa-Schittenhelm, Michael Walter, Marcus M Schittenhelm, Charles D. Lopez, Barbara Illing, Figen Akmut
Publikováno v:
Blood. 122:1270-1270
Apoptosis seems to be a major means by which p53 suppresses tumorigenesis in hematopoietic cells. While loss-of-function mutations in p53 are frequently found in most neoplasms, non-complex karyotype acute leukemias are typically p53 wildtype and the
Publikováno v:
Blood. 122:3856-3856
Introduction Constitutive phosphorylation of AKT is frequently found in acute leukemia. In a proportion of patients, activation of the PI3K/AKT pathway can be linked to gain-of-function tyrosine kinase mutations. We have previously shown that TKI onl
Autor:
Gunnar Blumenstock, Charles D. Lopez, Konstanze Döhner, Marcus M Schittenhelm, Kerstin M Kampa-Schittenhelm, Barbara Illing, Figen Akmut
Publikováno v:
Blood. 122:3770-3770
Introduction Inactivation of the p53 pathway is a frequent event in human cancers promoting tumorigenesis and resistance to chemotherapy. Inactivating p53 mutations are uncommon in non-complex karyotype leukemias suggesting that the p53-pathway must